US equities
|
NVDA
$240.64
▲+0.73%
SPCX
$173.83
▲+1.60%
MU
$1,067.69
▲+0.35%
MRVL
$285.66
▲+5.31%
AMD
$655.89
▲+3.82%
SNDK
$1,676.50
▼-1.62%
AVGO
$378.70
▲+4.47%
INTC
$113.09
▼-2.67%
NVDA
$240.64
▲+0.73%
SPCX
$173.83
▲+1.60%
MU
$1,067.69
▲+0.35%
MRVL
$285.66
▲+5.31%
AMD
$655.89
▲+3.82%
SNDK
$1,676.50
▼-1.62%
AVGO
$378.70
▲+4.47%
INTC
$113.09
▼-2.67%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Castle Biosciences, Inc. - Common stock
(NQ:
CSTL
)
34.06
-2.59 (-7.07%)
Delayed Quote
Updated: 12:35 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Castle Biosciences, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
↗
August 13, 2026
Castle Biosciences (NASDAQ:CSTL) reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its...
Via
MarketBeat
Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Revenue hit $103.5 million, up 20% YoY, as TissueCypher surged 63%.
Via
The Motley Fool
Topics
Earnings
Castle Biosciences Q2 Earnings Call Highlights
↗
July 30, 2026
Castle Biosciences (NASDAQ:CSTL) reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported...
Via
MarketBeat
Topics
Earnings
Castle Biosciences (NASDAQ:CSTL) Surges After Smashing Q2 Estimates and Raising Guidance
↗
July 30, 2026
Via
Chartmill
Castle Biosciences Inc (NASDAQ:CSTL) Beats Q1 Estimates, Raises Full-Year Guidance
↗
May 06, 2026
Via
Chartmill
Castle Biosciences Inc (NASDAQ:CSTL) Reports Q4 2025 Revenue Beat Amid Profitability Transition
↗
February 26, 2026
Via
Chartmill
Castle (CSTL) Q1 2026 Earnings Transcript
↗
May 06, 2026
Castle (CSTL) Q1 2026 Earnings Transcript
Via
The Motley Fool
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
March 13, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 09, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
This $56 Million Sale Slashed One Fund's DigitalBridge Stake Amid 49% Stock Surge
↗
March 05, 2026
DigitalBridge Group operates at the forefront of digital infrastructure, managing assets critical to global connectivity and data growth.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
This Fund Just Disclosed a $29 Million Sale of a Beauty Stock Up 20% This Past Year
↗
March 05, 2026
e.l.f. Beauty delivers cosmetics and skin care through a multi-channel model, with recent filings highlighting strong revenue growth.
Via
The Motley Fool
Topics
Regulatory Compliance
What's Behind This $32 Million Bet on Baidu Amid a 36% Stock Rally?
↗
March 05, 2026
Baidu delivers online marketing, cloud, and AI-powered services to businesses and consumers across China’s digital economy.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Regulatory Compliance
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
March 04, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
March 03, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences (CSTL) Earnings Transcript
↗
February 26, 2026
Castle Biosciences (CSTL) Earnings Transcript
Via
The Motley Fool
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
February 26, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
February 19, 2026
Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported...
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
February 05, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit
↗
February 03, 2026
This telecom provider delivers fiber, cloud, and security services to businesses and consumers across U.S. and international markets.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares
↗
February 02, 2026
This semiconductor company provides integrated RF and mixed-signal solutions for broadband, wireless, and industrial connectivity.
Via
The Motley Fool
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen)
↗
January 15, 2026
Via
Chartmill
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
January 14, 2026
Via
AB Newswire
Topics
Intellectual Property
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
January 11, 2026
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
December 17, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
December 12, 2025
Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
December 09, 2025
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
November 17, 2025
Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development
From
Castle Biosciences, Inc.
Via
GlobeNewswire
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
November 14, 2025
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor...
From
Castle Biosciences, Inc.
Via
GlobeNewswire
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
November 11, 2025
From
Castle Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
